BoomRay Licenses Preclinical Radioligand Asset to Novartis for $900M
Suzhou – September 22, 2026 -- Boomray Pharmaceuticals Co., Ltd. has signed an exclusive global license agreement with Novartis Pharma AG for an undisclosed preclinical radioligand therapy (RLT) asset, with total deal value reaching up to USD 900 million.
Novartis secures rights to undisclosed preclinical oncology asset
Under the agreement, BoomRay will be eligible to receive an upfront payment plus development, regulatory, and sales milestone payments totaling up to USD 900 million. The Suzhou-based company will also earn royalties on future global net sales of the licensed program.